A curcumin-loaded biopolymeric nanocomposite alleviates dextran sulfate sodium induced ulcerative colitis via suppression of inflammation and oxidative stress

Therapeutic potential and underlying mechanisms of phytoconstituents: emphasizing on resveratol, curcumin, quercetin, berberine, and hesperidin in ulcerative colitis

Ulcerative colitis is a long-term inflammatory colon illness that significantly affects patients quality of life. Traditional medicines and therapies often come with challenges such as side effects, instability, unpredictability, and high costs. This has captured interest in natural products that have huge health benefits. Various natural compounds, including resveratrol, curcumin, quercetin, berberine, and hesperidin demonstrate immunomodulatory and oxido-inflammatory properties inside the gut epithelium, showing potential in managing ulcerative colitis. These compounds attenuate inflammatory mediators, NF-κB, and TLR4 signaling leading to a reduction in the production of inflammation-related cytokines, including TNF-α and IL-6. They also augment the activity of internal defense compounds, including superoxide radical dismutase enzyme and heme oxygenase-1, thereby alleviating oxidative damage. In addition, natural compounds have a profound effect on the endogenous microbiota and thus, support mucosal healing and intercellular barrier integrity. Both experimental and clinical analyses provide evidence that these bioactive compounds may help reduce clinical manifestations, induce and sustain remission, and improve the well-being of individuals suffering from ulcerative colitis. This review seeks to discuss various aspects of natural compounds in the management of ulcerative colitis, including mechanisms, therapeutic prospects, and hurdles, and hence the basis for future research and practice.

Large Yellow Croaker Roe Protein Isolates/Gellan Gum Hydrogels Improve the Alleviating Effect of Curcumin on DSS-Induced Colitis

In this study, large yellow croaker (Pseudosciaena crocea) protein isolates/gellan gum (PG) binary hydrogels with dense microstructure were used for embedding and delivery curcumin (Cur). The colitis-relieving effects of PG-Cur were further investigated using the dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) mouse model. Following PG-Cur treatment, weight loss, diarrhea, and shortening of the colon were significantly alleviated. Compared with the free Cur group, weight loss and colon length in the PG-Cur group increased about 1.05- and 1.12-fold. IL-1β, IL-6, TNF-α, and IL-10 levels in PG-Cur group were not significantly different from those of the normal mice, and the MPO and iNOS activities of the PG-Cur group were 29% and 20% lower than those in the Cur group, respectively. Moreover, fecal microbiota analysis of mice revealed that PG-Cur effectively restored gut dysbiosis in DSS-induced colitis, enriching beneficial bacteria while reducing harmful ones. Overall, the PG hydrogels have the potential to serve as carriers for oral curcumin formulations aimed at alleviating UC.